Target Other Income (Expense) remained flat by 0.0% to $23.75M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 10.4%, from $26.50M to $23.75M. Over 2 years (FY 2023 to FY 2025), Other Income (Expense) shows relatively stable performance with a 1.6% CAGR.
An increase suggests higher non-operating gains or lower non-operating costs, while a decrease indicates higher non-operating expenses or lower non-operating income.
Represents the net total of non-operating financial activities, including interest income, interest expense, foreign cur...
Standard across all public companies; peers in the medical device sector often show similar volatility due to currency fluctuations.
other_income_expense_net| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $92.00M | $106.00M | $95.00M |
| YoY Change | — | +15.2% | -10.4% |